Eisai Co Ltd - Company Profile
Powered by 
All the data and insights you need on Eisai Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Eisai Co Ltd Strategy Report
- Understand Eisai Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Eisai Co Ltd (Eisai) is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex, a proton pump inhibitor; Aricept, an anti-Alzheimer agent; perampanel, Halaven, an anti-cancer agent; Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China, and India and laboratories in Japan, the US and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.
Headquarters
Japan
Address
Eisai Main Bldg., 4-6-10, Koishikawa, Bunkyo-Ku, Tokyo, 112-8088
Website
www.eisai.co.jp
Telephone
81 3 38173700
No of Employees
11,076
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4523 (TYO)
Revenue (2023)
$5.5B
-1.6%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
15.6%
(2023 vs 2022)
Market Cap*
$15.2B
Net Profit Margin (2023)
XYZ
17.5%
(2023 vs 2022)
* As of and is in US$
Eisai Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Pariet (proton-pump inhibitor) | Aricept |
| Aricept - Alzheimer's Disease/Dementia with Lewy Bodies | Iomeron |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Corporate Changes/Expansions | In September, the company established a digital business company, Theoria technologies Co., Ltd. |
| 2023 | Regulatory Approval | In May, the company received a New Drug Submission (NDS) acceptance from Health Canada for its product lecanemab. |
| 2023 | Contracts/Agreements | In May, the company signed an agreement with Bliss Biopharmaceutical to develop antibody-drug conjugate (ADC), BB-1701, to treat cancers. |
Competitor Comparison
| Key Parameters | Eisai Co Ltd | Takeda Pharmaceutical Co Ltd | Astellas Pharma Inc | Chugai Pharmaceutical Co Ltd | Ono Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Bunkyo-Ku | Chuo-Ku | Chuo-Ku | Chuo-Ku | Osaka-Shi |
| State/Province | Tokyo | Tokyo | Tokyo | Tokyo | Osaka |
| No. of Employees | 11,076 | 49,095 | 14,484 | 7,771 | 3,761 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Yasuhiko Katoh | Chairman | Executive Board | 2018 | - |
| Haruo Naito | Chief Executive Officer; Director; Representative Corporate Officer | Executive Board | 2014 | - |
| Ivan Cheung | Officer- Global Alzheimer's Disease; Chairman - Eisai Inc; Senior Vice President; Chief Executive Officer - Eisai Inc; President - Americas Region | Executive Board | - | - |
| Gary Hendler | Senior Vice President; President - EMEA Region; Chief Executive Officer - Eisai Europe Ltd; Chairman - Eisai Europe Ltd | Executive Board | - | - |
| Tatsuyuki Yasuno | President - Americas Region; Chairman - Eisai Inc; Chief Executive Officer - Eisai Inc; Senior Vice President | Executive Board | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward